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Abstract
Foot and mouth disease virus causes a livestock disease of significant global socio-economic importance. Advances in its
control and eradication depend critically on improvements in vaccine efficacy, which can be best achieved by better
understanding the complex within-host immunodynamic response to inoculation. We present a detailed and empirically
parametrised dynamical mathematical model of the hypothesised immune response in cattle, and explore its behaviour
with reference to a variety of experimental observations relating to foot and mouth immunology. The model system is able
to qualitatively account for the observed responses during in-vivo experiments, and we use it to gain insight into the
incompletely understood effect of single and repeat inoculations of differing dosage using vaccine formulations of different
structural stability.
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Introduction
Foot and mouth disease virus (FMDV) causes a highly infectious
disease of cloven-hoofed animals that has significant global socio-
economic impact. Foot and mouth disease (FMD) severely affects
the welfare and productivity of high-value farm animals that are
important to food security, including cattle, sheep and pigs ([1].
Disease-free status allows countries to participate in free trade of
animals and produce. However, the loss of such status, even
temporarily, can result in significant economic losses [2]. In
countries where FMD is endemic the disease results in enormous
losses, especially to small-scale livestock farmers, and it is ranked in
the top ten livestock diseases for cattle and pigs in terms of impact
on the poor globally [3].
Vaccination is one of the principle methods available for disease
control and eradication, and mathematical modelling has been
identified as playing a vital role in helping formulate effective
strategies [4]. Whilst there has been much epidemiological
modelling of FMD outbreaks and associated intervention strategies
(see for example reviews [5,6,7]) this has been on a regional scale
and hence at the farm-level. There exists little work focussing on
the within-host dynamics of infection with wild-type virus, or
modelling of immune responses to either infection or vaccination,
although data from complex experiments able to elucidate this are
now available [8,9,10].
FMD occurs as seven main serotypes (O, A, C, SAT1, SAT2,
SAT3, Asia1) with numerous antigen subtypes within each strain.
Vaccines tend to be most effective against the specific strain they
are designed to elicit protection. However, there is an urgent need
to develop better FMD vaccines which protect against a wider
range of strains and, more importantly, confer longer-lasting host
protection than existing formulations. Commercially available
FMD vaccines are based on inactivated virus grown in large-scale
cell culture. In many commercial livestock herds repeat vaccina-
tion is necessary to sustain host protection and, although costly,
this approach is used in many parts of the world where FMD is
endemic or sporadic. Consequently, improved vaccines would
contribute significantly to reducing the economic burden imposed
by FMD and improving food security.
Generating more effective FMD vaccines depends critically on
developing a better understanding of the basic host immunological
responses both to infection by wild-type virus strains and to
vaccination with antigenic formulations. Much detailed experi-
mental work on immune mechanisms has been undertaken in-vivo
and in-vitro and has generated a wealth of insight into various
aspects of host innate and adaptive responses (see for example
references in [11].
However, key issues relating to vaccine immunogenicity remain
unresolved. Juleff et al. [12] suggest that the repetitive antigenic
sites embedded in the stable conformational structure of the viral
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capsid (by virtue of the icosahedral symmetry) are essential to
stimulate a protective immune response to FMDV. Soluble
antigens, disrupted capsids or peptides are incapable of inducing
an equivalent response. The FMD virus is notoriously unstable, a
likely consequence of infectivity relying on acid-induced capsid
disassembly in endosomal vesicles following virus uptake from the
cell surface; although there is some variation in stability across the
serotypes [13]. As a result FMD vaccines are unstable in various
environmental conditions, including mild acidic pH and elevated
temperatures (as when the cold chain is broken). The instability of
the icosahedral capsid is manifest as dissociation into smaller
pentameric assemblies with a consequent loss of immunogenicity
and this is an important concern for all FMD vaccines. Increased
FMD vaccine stability is therefore a highly sought goal, not only
for enhanced storage characteristics but also to increase duration
of immunity. Using a mathematical model we are able to
investigate the effect that vaccine stability has on within-host
adaptive immune responses. Here adjuvant is included implicitly
in the model, since the vaccine doses we are investigating are
based on the observed properties of commercial veterinary
preparations. The benefits these bring are generally assumed to
have been optimised, but what is of interest here is it working
within the known limitations of existing products. Moreover, using
the model it is possible to explore the interplay of varying dose,
repeat vaccination frequency and vaccine stability, all of which are
features of vaccination protocols in veterinary practice. In doing
this we exploit previous experimental work on FMD immunology,
and moreover, formalise proposed immune response mechanisms
against FMD in a mathematically consistent framework.
Specifically, we develop and parametrise a detailed dynamical
model of the proposed within-host adaptive immunological
response mechanism to inoculation with vaccine formulations of
differing structural stability. The model is able to qualitatively
account for empirically observed dynamics of the various
constituent cell types in the coordinated immune response to the
presence of antigen, as well as the generation of immune memory,
thereby giving confidence that the proposed mechanism is an
appropriate one. Moreover, it shows how repeat host vaccination
and compensation of structural stability for dose can be used to
maintain elevated levels of host protection. Results also indicate
that capsid stability has no impact on the timing of the immune
response though it has significant impact on its magnitude. Recent
experimental work on antigen formulations that are either T-cell
dependent or T-cell independent show a significant difference in
the resultant immunoglobulin levels in cattle, and we show how to
use the model to account for these observed immune dynamics.
The specific effects of the stability and dose, individually and in
combination, could not be clarified without developing a
dynamical model that captures the essential components of the
immune response.
The mathematical model complements existing experimental
approaches to FMD immunology, and is intended to be used as a
framework within which to formalise thinking about hypothesised
immune mechanisms, and in the development of future experi-
ments. Given the current level of knowledge with regard to bovine
immunology, and the difficulties of deriving quantitative data on
key factors from experiments, we believe that at present a coarse-
scale model is the most appropriate for investigating this system.-
The model as it is presented and parameterised gives confidence
that currently proposed immune mechanisms are sound, and
furthermore it can be used as a point of departure to explore
possible outcomes before additional experimental work is
undertaken. In this way we aim to advance understanding of
which potential future improvements in vaccine technology will be
most efficacious.
We describe a hypothesised immune response to the presence of
vaccine antigen (see Figure 1) and discuss viral capsid stability. The
structure of the full immunological model and a review of the
assumptions inherent in its development are presented in the
Materials and Methods. Parameter estimates for the model are
also presented here. The model is then used to explore the
dynamics of the immune response to host inoculation with vaccine
formulations of varying dose and stability, and these are discussed
in relation to a variety of empirical and experimental observations.
A model sensitivity analysis is also presented.
Results
The system of delay-differential equations (1)–(13), describing
the dynamics of the variables listed in Table 1, was numerically
integrated using the Runge-Kutta method, implemented through
the dde23 routine in Matlab R2010a [14]. This permitted
comparison of model outputs with experimental results. All
simulations used the nominal parameter values given in Table 2,
unless stated otherwise.
Effect of vaccine dose and stability
The results of a single dose (V0) of stable vaccine antigen being
introduced into the model system at time t~0 are given in
Figure 2. The model simulation showed an immune response
stimulated by vaccine antigen that lasted for several weeks: the
timescales observed for the different cell types and antibodies were
characteristic of those seen following immunisation of cattle [9].
Specifically the removal of vaccine antigen, V , on a fast
timescale was observed, together with the generation of a burst of
short-term antibodies that peaked around the second week after
immunisation. A longer-term antibody response AL was generat-
ed, which persisted over the host lifetime, remaining present to
immediately respond to future antigen challenges. A sustained,
Figure 1. Schematic of the short-term and long-term dynamics
of the immune response, as stimulated by vaccine antigen. For
variable definitions see Table 1; for parameter definitions and values see
Table 2.
doi:10.1371/journal.pone.0030435.g001
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elevated, population of memory B cells and long-lived plasma B
cells was also produced, which constituted the generation of
immunological memory.
We repeated the calculation but varied the initial dose of (stable)
vaccine antigen: results are given in Figure 3. The magnitude of
the immune response was clearly sensitive to the initial dose V0
and the qualitative form of the temporal dynamics was maintained
as we would expect. Although higher vaccine doses elicited
stronger immune responses, there was an upper bound due to
saturation of dendritic cells (i.e. the assumption that all local
dendritic cells present are stimulated and addition of more vaccine
does not lead to further immunological stimulation) but only at a
much higher vaccine dose than observed experimentally.
We next considered the effect of vaccine stability on the immune
response by varying the vaccine decay rate parameter dV : results are
given in Figure 4. Vaccine stability had an impact on the magnitude
of the immune response, with the more stable antigens stimulating
stronger responses in all cell types. However, stability had negligible
impact on the overall timing of the immune response.
These model results suggested that antigen dose can compensate
for stability within the estimated parameter ranges: specifically,
increasing the vaccine dose elicits an immune response compara-
ble with that of a more stable vaccine.
Effect of vaccine dose and stability on booster
vaccination
In the field, initial FMD vaccination often elicits transient host
protection and repeat vaccination is necessary to maintain
protective immunity: this is done at least twice a year where
practical (e.g. [15]). Using the model it was possible to investigate
the effect and observed cumulative benefit of repeat vaccination
with vaccine formulations of differing structural stability. Figure 5
shows the simulation results when a second (identical) vaccine dose
V0 was introduced 29 days after the first, and observed for a
further 42 days (71 days in total), reflecting the experimental
protocol referred to in Figure 6. We performed this calculation
both for stable and unstable vaccine antigens.
The system produced the response in IgM and IgG that would
be expected empirically, namely, only a small difference in IgM
(AS ) between the first and second dose but a much larger booster
effect in IgG (AL) for stable vaccine (blue data in Figure 6). This
effect was much larger than can be explained by the sum total of
doses alone. It was evident that the model is able to qualitatively
capture immunological memory, which is a central feature of the
adaptive immune response. As before, stable vaccines elicited a
stronger immune response, especially following secondary vacci-
nation. Antibody levels were maintained at a higher level, and for
longer, with increasing vaccine stability.
T-cell dependent responses – comparison with
experimental results
Figure 6 shows experimental IgM and IgG levels in cattle
immunised twice – an initial dose at t~0 and an equal booster dose
at t~29 days – with two different vaccines. One vaccine was
modelled on a conventional, commercial vaccine (data plotted in
blue) that initiates the full immune response. The second was a
modified vaccine (data plotted in green) that is designed not to fully
initiate a T-cell dependent response. We note that in the latter case
there was still some generation of IgG-secreting B-cells, and thus
IgG (Figure 6, bottom right), although much reduced. The principle
difference is a significant reduction in the IgG response to a booster
dose of vaccine in the absence of a T-cell mediated response.
Although the data is best considered qualitatively, using the
model we investigated the effect of repeat vaccination with such
modified antigens: an inhibited T-cell independent response was
represented by reducing cDUDM and cDUDF in equations (10)–(13);
results are given in Figure 7. Since the T-cell mediated response is
an intrinsic component of the long-term (adaptive) pathway that
generates IgG, and assumed to require more sustained stimulation,
while IgM is produced by the short term pathway only, we
considered the data presented in Figure 6 as a guide to the
response expected from stable and unstable (i.e. slowly and rapidly
decaying) vaccine.
Although the model only aims to qualitatively replicate observed
dynamics, we have plotted experimental results and simulation
results together in Figure 8 for comparison. Bearing in mind that
the success of the experimental protocol in removing T-cell
dependence is unknown, we believe that the model is also able to
produce good agreement with the observations for this scenario.
Sensitivity analysis
We have shown that the model for the within-host immune
responses to immunisation with FMDV vaccine antigens of
differing stability can lead to realistic qualitative behaviours using
plausible sets of estimated model parameters. This indicates that
the mathematical model is capable of successfully reflecting the
inherent dynamics of the immunological response. However, our
model was complex, involving a large number of state variables
(13) and model parameters (34). The notional values for the model
parameters were estimates but, inevitably, there was some range of
uncertainty within which their precise values actually lie. When
structural complexity of a mathematical model is allied with model
parameter uncertainty it is useful and desirable to be able to
systematically assess the likely variation in the results of the model
in order to establish whether the sorts of behaviours seen in the
output are robust over a broad range of parameter choices. For
models to be useful the successful application of such an
uncertainty assessment gives confidence that the observed output
is not simply a fortuitous combination of model parameters.
Figure 9 shows the sensitivity analysis for a LHS scaling factor of
4 (i.e. each parameter is uniformly distributed between
1
4
to 4 times
its estimated value). It is evident that the qualitative behaviour of
Table 1. Variables.
Variable Interpretation
V vaccine concentration
BS short term antibody secreting cell concentration
BL short term T-cell dependent antibody secreting cell concentration
BN long term T-cell dependent antibody secreting
(long-lived plasma) cell concentration
BM memory B cell concentration
TE effector T cell concentration
TM memory T cell concentration
C antigen-antibody complex concentration
DU non-activated dendritic cell concentration
DM activated DC level via macropinocytosis
DF activated DC level via the FC activation process
AS short term memory antibody IgM concentration
AL long term memory antibody IgG concentration
Definitions of system variables.
doi:10.1371/journal.pone.0030435.t001
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the model was preserved for up to this multiple; comparable IgM
(AS ) responses following initial and booster vaccination were seen
and a significant enhancement in the magnitude of IgG (AL)
response was maintained. Other calculations (not shown) indicated
consistent model behaviour up to multiples of at least 6. This
indicates that the model of the T-cell independent and T-cell
dependent antibody responses is robust against large uncertainty
in the model parameters.
A key feature of the dynamics is the booster effect in IgG (AL),
and the metric we used to evaluate whether this is preserved was
the ratio of peak responses following the first and second dose of
vaccine; explicitly:
RAL~
maxtƒtAL
max0ƒtvtAL
:
Table 2. Parameters.
Parameter Interpretation Value{ Source/justification
bDU Dendritic cell migration rate 3.0 wk
{1 95% repopulation within 1 week after local removal
bASBS IgM production by short-term ASC rate 2.0 wk
{1 observed initial growth rate (see Figure 6)
bALBL IgG production rate by short-term T-cell dependent ASC ’’ &bASBS
bBSV short-term ASC production rate 6.9 wk
{1 &dBS
bBLTE short term T-cell dependent ASC production rate ’’ &bBSV
bBNTE long-term T-cell dependent ASC production rate ’’ &bBLTE
bTMDF memory T-cell production by FC activated DCs rate 0.17 wk
{1 2{3% increase per day ([28]: p2 Table 1 – CD4 CD45R0)
bTMDM memory T-cell production by macropinocytosis activated DCs rate ’’ &bTMDF
bTEDF effector T-cell production by FC activated DCs rate ’’ &bTMDF
bTEDM effector T-cell production by macropinocytosis activated DCs rate ’’ &bTMDF
bBMTE memory B-cell production rate 0.17 wk
{1 2{3% increase per day ([28]: p2 Table 1 – CD19 CD27+)
bALBN IgG production rate by long-term T-cell dependent ASC 1.36 wk
{1 &dAL
cTMTE memory to effector T-cell conversion rate 1 wk
{1c{2
cVCS vaccine-IgM complex formation rate 2 wk
{1c{1 Observed in less than 1 hour
cVCL vaccine-IgG complex formation rate ’’ &cVCS
cDUDM Vaccine uptake rate by micropinocytosis 1.4 wk
{1 5% of final take up achieved within 6 hours (unpublished
data)
cDUDF Complex uptake rate by FC activated pathway 19 wk
{1 50% of final take up achieved within 6 hours (unpublished
data)
ltirow2*dV { unstable vaccine decay rate 39 wk{1 in-vitro half-life of 3 hrs [13]
stable vaccine decay rate 19 wk{1 in-vitro half-life of 6 hrs [13]
dC antigen-antibody complex decay rate 17 wk{1 loss: 50% in 5 hrs, 90% in 30 hrs [29]
dDM macropinacytosis-activated DC decay rate 13 wk
{1 lifespan of 2–3 days (unpublished data)
dDF FC-activated DC decay rate ’’ ~dDM
dTE effector T-cell decay rate 4.7 wk
{1 cleared within 1 week (unpublished data)
dTM memory T-cell decay rate 0.51 wk
{1 7% loss per day ([28]: p2 Table 1 – CD4 CD45R0)
dBM memory B-cell decay 0.43 wk
{1 6% loss per day ([28]: p2 Table 1 – CD19 CD27+)
dBS short-term ASC decay rate 0.69 wk
{1 half life of 1 week (unpublished data)
dBL short-term T-cell dependent ASC decay rate ’’ &dBS
dBN long-term T-cell dependent ASC decay rate 0.01 wk
{1 half-life of order one year
dAL IgG decay rate 1.36 wk
{1 dALzcVCLV0 combined decay rate of 3.36 (see Figure 6)
dAS IgM decay rate 0.17 wk
{1 dASzcVCSV0 combined decay rate of 2.17 (see Figure 6)
Vc half-saturation of vaccine uptake by unactivated DCs 20 c Saturation at 30–40 times standard dose (unpublished
data)
Cc half-saturation of complex uptake by unactivated DCs 0.1 c
D0 baseline non-activated dendritic cell concentration 1 c
tB time-delay in B-cell response to vaccine 0.14 wks observed within 1 day (unpublished data)
tT time-delay in T-cell response to activated DCs 0.57 wks observed within 4 days (unpublished data)
Definitions of system parameters and values used in simulations (with justification and/or reference source). Here b generally refers to production rates, c to conversion
rates, d to decay rates and t to temporal delays. For simulations we consider V0~1.
{wk: week; c{1 : particle (vaccine, complex or cell) concentration.
doi:10.1371/journal.pone.0030435.t002
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A systematic exploration of the peaks ratio observed for IgM and
IgG is shown in Figure 10: ratios greater than 1 were usually
observed over parameter multiples up to at least 6 times nominal. As
parameter uncertainty increased (i.e. the scaling factor increased)
the observed magnitude of theT -cell dependent antibody response
decreased, on average (but with higher variability).
Figure 2. Model results for the system with initial vaccination at time t~0, with parameters as given in Table 2 and ‘‘stable’’
vaccine.
doi:10.1371/journal.pone.0030435.g002
Figure 3. Model results for the system with different initial doses of (stable) vaccine: V0 (solid), 2V0 (dashed), 10V0 (dot-dashed) and
V0=2 (dotted).
doi:10.1371/journal.pone.0030435.g003
Immune Response to Vaccine Stability and Dose
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Discussion
We have developed a mathematical model of the bovine
immune response to FMDV vaccination, incorporating detailed
representations of the T-cell independent and T-cell dependent
antibody responses. Such models have helped to further our
understanding of the mechanisms involved in adaptive immune
responses to host challenge with live pathogens and vaccine
Figure 4. Model results for the system with stable (blue) and unstable (red) vaccine, the latter having a decay rate dV roughly twice
that of the former (see Table 2). The benefits of stability are not fully realised until a booster dose is applied (see Figure 5).
doi:10.1371/journal.pone.0030435.g004
Figure 5. Model results for the system with stable (blue) and unstable (red) vaccine, in response to a second (booster) vaccine dose
administered approximately 4 weeks after the initial one.
doi:10.1371/journal.pone.0030435.g005
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antigens [16]. The model reflects the interactions of the principle
cell types and antibodies that are thought to be responsible for
establishing and maintaining immunity within the host. It is
concerned with the CD4+ response and does not include the
effects of CTL (cytotoxic T lymphocyte CD8+), since at present
there is no evidence that FMDV vaccination stimulates a
protective CD8+CTL response. Using the model we have been
able to address a number of empirical issues relating to FMDV
vaccination. Our motivation has been to provide an explanatory
framework within which it is possible to connect hypotheses about
detailed mechanisms with experimental data. Moreover, we have
attempted to identify many of the relevant parameters that govern
the interactions and dynamics of the different cell types.
The model is able to replicate in-vivo observations of
immunoglobulin dynamics, which lends support to the currently
hypothesised immunological response mechanism. The model
includes two distinct pathways: short term B-cell production and
longer production of target T-cells that drive prolonged antibody
responses. Analysis of these produces the behaviour consistent with
experimental observations, including the timings of the peak in the
long and short term antibody responses. The explicit inclusion of
clearly identified parameters which govern specific aspects of the
system, such as antibody mediated uptake, allow for the influence
of each of these to be explored.
We investigated whether it was possible to mitigate deficiencies
in vaccine stability by inoculating with a higher dose of vaccine.
This is a question of some significant practical importance. The
model results suggest that it is possible to compensate for poor
stability with increased dose, but empirically it is found that whilst
this is true there is a saturation effect [17]. This is replicated in the
model although only at much higher doses than those presented
here.
Results suggest that vaccine stability may not have a
pronounced impact on the timing of the T cell response, but will
affect its magnitude – and hence duration. Future work will look in
more detail to how these predictions compare with experimental
evidence that vaccine produced from different virus serotypes can
differentially stimulate T cell responses. In addition, we were able
to use the model to account for experimental results involving
conventional and modified vaccine formulations. Results present-
ed here motivate experimental study of additional serotypes with
assumed differential stability and T-cell response inducing
properties.
The system achieves good qualitative agreement with empirical
observations of the system response to booster vaccine doses, and
suggests that stable vaccine benefits more from multiple doses. We
undertook a LHS sensitivity analysis which demonstrated the
robustness of the immunological model under significant param-
eter uncertainty. However, it will be necessary to provide better
estimates of some of the parameters in the model: in particular, we
are considering how the deficit in data regarding the local
saturation of DCs can be remedied. We acknowledge that while
it would be ideal for all parameters to be derived from experiments
using FMDV vaccine in cattle, a number (e.g. those relating to cell
production rates) come from other systems. These are the best
available at present and, we believe, in each case an appropriate
proxy that does not significantly change subsequent results.
The model provides a consistent representation of immune
responses to vaccination and will be used to inform future
experimental investigations aimed at enhancing commercial
vaccine efficacy. Our model can also be utilised to interrogate
the immune response to T-dependent (T-D) and T-independent
(T-I) antigens. Antigens that require T-cell help to orchestrate a
high affinity class-switched serological response are termed T-D
Figure 6. In-vivo experimental results for cattle inoculated with a regular dose of vaccine at 0 and 29 days, giving the resultant IgM
(left) and IgG (right) levels recorded: (top: blue) normal vaccine producing a regular immune response; (bottom: green) vaccine
stimulating the T-cell independent response only. Plots give the median value (central bar), 25th–75th percentile (box) and extreme values
(whiskers) unless considered outliers, in which case they are plotted separately (cross) for four (bottom: T-cell independent) or five (top: T-cell
dependent) replicates (individual cattle). Data from [9]. Note the significant differences in magnitude between the T-cell dependent and T-cell
independent cases. Results presented on a log-scale.
doi:10.1371/journal.pone.0030435.g006
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Figure 7. Model results for the full system (blue) and for the system with a reduced T-cell dependent response only (green), where
ªDUDM and ªDUDF have been reduced to 1%of their original values. All figures present variables on a log scale as percentages of their peak value.
doi:10.1371/journal.pone.0030435.g007
Figure 8. Experimental and simulation results for IgM (AS ) and IgG (AL) for the full system (blue) and for the system with a reduced
T-cell dependent response only (green). Here the mean and range of each of the datasets from Figure 6 are plotted, together with the
simulation results from Figure 7, with the model outputs suitably scaled (the peak of the experimental mean for each of the two immunoglobulins
matched by the peak of the full T-dependent system).
doi:10.1371/journal.pone.0030435.g008
Immune Response to Vaccine Stability and Dose
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antigens. T-I antigens are able to initiate a serological response in
the absence of T-cell help but show little germinal centre
formation or B-cell memory. There are two types, type I
(polyclonal B-cell stimulant) or type II (non-polyclonal stimulant).
It has been demonstrated that T-I antigens can be altered, via
conjugation of a protein carrier, to produce a T-D immunological
Figure 9. LHS applied to the immunological model with parameter ranging from
1
4
to 4 times the nominal values shows that
qualitative behaviour is maintained. Here the median (solid line) is plotted together with the range of possible results, in 5 percentile steps
(shaded) from 410 replicates (axes upper bound set at maximum of 95th percentile range) on a log scale.
doi:10.1371/journal.pone.0030435.g009
Figure 10. The peaks ratio for IgM and IgG of replicates with variable parameter values selected using LHS, for different multiples.
Plots give the median (red bar), 25–75th percentile (box plot), non-outlier range (whiskers) and outliers (red cross) for each multiple set. In addition
the ratio from the estimated parameter set is marked (magenta) together with the value 1 (cyan), where the ratio would switch from an increase to a
decrease and which would represent a significant qualitative change in dynamics.
doi:10.1371/journal.pone.0030435.g010
Immune Response to Vaccine Stability and Dose
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response resulting in induction of a more sustained immunological
memory response [18,19]. Our model has the potential to predict
the experimental outcome of enhancing T cell stimulation to drive
enhanced B cell responses and long term protective antibody
responses.
Mathematical modelling of within-host immunological respons-
es to infection with replicating viruses has been valuable in
clarifying and describing the most significant immunological
interactions and mechanisms [16,20,21]. By contrast, equivalent
studies that model the interaction of vaccine formulations with
host immune systems are much less well developed. Here we have
initiated a similar approach to understanding the interaction of
vaccine candidates with immunological responses, and we seek to
promote the use of mathematical modelling as an integral
component of vaccine development.
Materials and Methods
Immune system and antigenic stability
We aim to describe the classical adaptive immune response in as
simple a way as possible while including all essential components.
The system consists of two principle pathways, referred to as the
‘‘short-term’’ and ‘‘long-term’’ pathways, which are described in
detail below. The process is driven by the presence of antigen (in
this case vaccine capsid), which initiates the production of T-cells
and specialist B-cells that are capable of producing the appropriate
antibodies. These antibodies combine with free capsid (and, more
importantly, with the relevant wildtype virus if it is present in
future) to form a complex that is then removed from the system.
Vaccine capsids are designed not to interfere or inhibit any of
the immune response processes, unlike most pathogens and many
other external agents that the immune system is required to deal
with. FMDV vaccines appear successful in this regard, and we
therefore consider the system as closed.
Short-term (T-cell independent) pathway
Following inoculation vaccine capsid (V ) passes, via the
lymphatic system, into the lymph nodes. Here the antigen markers
on the capsid surface stimulate a cascade of responses that will, in
time (following a delay tB), generate targeted B-cells (BS ) which, in
turn, release into the body specifically-targeted antibodies, namely
immunoglobin IgM (AS ) [22]. This antibody binds with the free
capsids to form a capsid-antibody complex (C) that, although
inert, is involved in the long-term pathway (see below). After the
antigenic stimulus is removed, the specific B-cell population, and
consequently antibody production, will decline to negligible levels
over a period of a few weeks. We assume that this pathway has no
inherent memory so that any future insults, either by virus or
vaccine, will initiate the process anew. The T-cell independent
pathway does not produce long lived memory cells [23].
Long-term (T-cell dependent) pathway
Vaccine capsid is also delivered to the lymph nodes by specialist
antigen presenting dendritic cells (DCs), which stimulate a
different set of responses to that of the short-term pathway.
Unactivated DCs (DU ) are present throughout the body, and can
become activated either by direct uptake of the capsid particles
through macropinocytosis (DU?DM ) or by uptake of the capsid-
antibody complex via the FC receptor mediated process
(DU?DF ). These activated DCs migrate to the lymph-node to
present the antigen to naive T-cells, which in time (following a
delay tT ), mature to either effector T-cells (TE ) or memory T-cells
(TM ). Effector T-cells in turn stimulate development of a new line
of differentiated B-cells capable of producing immunoglobin IgG
antibodies (AL); these B-cells may be short-lived (BL) or long-lived
plasma (BN ) cells, depending on whether they colonize in the bone
marrow. The latter are often referred to as ‘‘niche’’ cells since they
settle in niches in the bone marrow. In addition, effector T-cells
also stimulate memory B-cells (BM ) that interact with memory T-
cells and vaccine capsid (V ) to generate additional effector T-cells:
this T-cell dependent antibody response allows for a much more
rapid response to ‘‘booster’’ vaccine doses – or exposure to live
virus – in future.
The full integrated system, comprising of the short-term and
long-term pathways, is illustrated in Figure 1 in terms of the
population variables and parameters defined in Tables 1 and 2
respectively, and is in broad agreement with that described by
Goodnow et al. [24].
Capsid stability
The structural stability of the complex protein envelope
surrounding the RNA of the virus (the capsid envelope), upon
which most FMD vaccine formulations are based, appears to be
influential in determining the degree of protection afforded by the
vaccine. Comparison of the thermal stability of FMD A and SAT2
strains incubated at 49uC indicated an approximately 40-fold
difference in the decay rate of live virus [13]. Given the enhanced
immunogenicity engendered by more stable capsid particles we use
the relative capsid decay rate as a metric of stability in the model.
Compartmental model
The model equations are derived from the pathways shown in
Figure 1 under the assumption of mass action laws and
exponential decay where appropriate. The variables represent
concentrations i.e. cell number per unit volume. Most parameters
represent rates, either production (b), conversion (c) or decay (d).
In the absence of data on exactly how delays in the system are
distributed, we model the time for B-cell and T-cell generation as
simple discrete temporal delays.
The temporal evolution of the vaccine antigen is determined by
its decay rate, uptake by IgM (AS), uptake by unactivated DCs
(DU ) and uptake by IgG (AL), which are explicitly given by:
dV
dt
~{dV V{cVCSVAS{cDUDMDU
V
VzVC
 
{cVCLVAL, ð1Þ
The decay rate parameter dV describes the stability of the vaccine
capsid (with a half-life given by ln 2=dV ). Here cVCS and cVCL are
the rate at which vaccine-IgM complex and vaccine-IgG complex
form respectively, while cDUDM is the rate of vaccine uptake by
micropinocytosis.
Although only a tiny proportion of DCs will be activated
through vaccination, it is expected that local saturation will occur
temporarily. We therefore assume that there exists a preferred
inactivated DC concentration to which levels slowly return
following uptake, and that the activation rate of DCs obeys
Michaelis-Menten kinetics. Unactivated DCs (DU ) are taken up by
antigen (V ) or complex (C) so that:
dDU
dt
~bDU D0{DUð Þ{
cDUDMDU
V
VzVC
 
{cDUDFDU
C
CzCC
  ð2Þ
Here VC and CC are the level of vaccine and complex respectively
resulting in 50% saturation of unactivated DCs. cDUDF is the rate
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of uptake of complex by the FC activated pathway, while bDU is
the rate of dendritic cell migration.
Under the assumption that the level of vaccine in the lymph
nodes is proportional to the total level, the dynamics of the short-
term antibody secreting B-cells and subsequent short-term IgM
concentration are given by
dBS
dt
~bBSVV (t{tB){dBSBS, ð3Þ
dAS
dt
~bASBSBS{cVCSVAS{dASAS: ð4Þ
dBS and dAS are the natural decay/removal rate of short term
antibody secreting cells (ASCs) and IgM respectively, while bBSV
and bASBS are the rate of production of short-term ASC induced
by vaccine and the rate of IgM production by short-term ASC.
The production of these B-cells takes a time tB and is thus
dependent on the vaccine concentration at a time in the past.
IgM is produced in proportion to the number of B-cells and is
lost through binding with vaccine antigen and through decay. In
the absence of vaccine V , both BS and AS decay to zero as
expected.
The generation of the vaccine–antibody complex through the
long-term pathway is a result of vaccine binding with IgM and
IgG, with loss as a result of uptake by unactivated DCs and natural
decay. We do not distinguish between vaccine–IgM and vaccine–
IgG complex, since once they are formed the properties of these
complexes are very similar. DCs are activated by vaccine uptake
via macropinocytosis or via FC activation, but with saturation, and
lost through decay, giving:
dC
dt
~cVCSVASzcVCLVAL{cDUDFDU
C
CzCC
 
{dCC, ð5Þ
dDM
dt
~cDUDMDU
V
VzVC
 
{dDMDM , ð6Þ
dDF
dt
~cDUDFDU
C
CzCC
 
{dDFDF : ð7Þ
Here dC , dDM and dDF are the decay rates of complex,
macropinacytosis-activated DCs and FC-activated DCs respec-
tively.
The presentation of vaccine or complex derived antigenic
peptides by activated DCs to naive T-cells generates two classes
of T-cells, with the differentiation of naive T-cells assumed to
take a time tT . Furthermore, memory T-cells can be converted
to effector T-cells by memory B-cells in the presence of vaccine,
while memory B-cells themselves are produced in the presence of
effector T cells. B cell development is supported by T helper
cells.
The rate of decay of effector T-cells, memory T-cells and
memory B-cells is given by dTE , dTM and dBM respectively, so that:
dTE
dt
~bTEDMDM (t{tT )zbTEDFDF (t{tT )z
cTMTETMVBM{dTETE ,
ð8Þ
dTM
dt
~bTMDMDM (t{tT )zbTMDFDF (t{tT ){
cTMTETMVBM{dTMTM ,
ð9Þ
and
dBM
dt
~bBMTETE{dBMBM : ð10Þ
Here bTEDM and bTEDF are the rate of effector T-cell production by
macropinocytosis activated DCs and FC activated DCs respectively,
bTMDM and bTMDF are the rate of memory T-cell production by
macropinocytosis activated DCs and FC activated DCs respectively,
bBMTE is the rate of memory B-cell production and cTMTE is the rate
at which memory T-cells are converted to effector T-cells.
Effector T-cells give rise to B-cells, a proportion of which settle
in the bone marrow where their life span is significantly enhanced
(long-lived plasma cells). IgG is produced by both types of T-cell
dependent B-cells and can form complex with vaccine, giving:
dBL
dt
~bBLTETE{dBLBL, ð11Þ
dBN
dt
~bBNTETE{dBNBN , ð12Þ
dAL
dt
~bALBLBLzbALBNBN{cVCLVAL{dALAL: ð13Þ
It is assumed that negligible IgG is produced by the short-term
pathway, so that AL represent only T-cell dependent immuno-
globulin. The rates bBLTE , bBNTE , bALBL and bALBN represent
short term T-cell dependent ASC production, long-term T-cell
dependent ASC production, IgG production rate by short-term T-
cell dependent ASC and IgG production rate by long-term T-cell
dependent ASC respectively; dBL , dBN and dAL are the rates at
which short-term T-cell dependent ASC, long-term T-cell
dependent ASC and IgG decay.
Vaccine antigen (V ) is first introduced as an impulse at time
t~0 into a system of DCs (DU ), and we therefore impose the
following initial conditions:
V~
0, tv0,
V0, t~0,

and DU~D0 for tƒ0, with all other variables equal to zero. The
system is defined completely by the closed equations (1)–(13) and
these initial conditions. When a ‘‘booster’’ vaccine dose is applied
at time t~t, we introduce an impulse of the form
V (tz)~V (t{)zV1;
this means that immediately after the timepoint t the value of V
has increased by a quantity V1 compared to immediately before
time t. All model variables are given in Tables 1.
Parameter estimates
The immunology of FMDV has been intensively studied in a
variety of in-vivo and in-vitro contexts. Because of this, and perhaps
unusually for an immunological system, we are able to make good
estimates for many of the parameters in our detailed model.
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Parameter values for the immune model are taken from the
literature or estimated from recent experimental results at the
Institute for Animal Health – Pirbright Laboratory; where
possible, we have sought to do so from experiments relating to
FMDV infection in cattle or inoculation with antigens. The
nominal parameters for our model are summarised in Table 2,
together with sources for each parameter estimate. Although
estimates for a number parameters are not available – and there is
no way at present to extract these numbers experimentally – it is
still possible to make progress by numerical simulation and
analysis of the model without them. We have undertaken
sensitivity analysis to capture the uncertainty these introduce,
and noted which parameters primarily result in the scaling of
certain variables. In what follows we therefore restrict our
attention to the relative rather than absolute levels of IgG (AL)
and IgM (AS ) in response to different scenarios, and when
comparing output to experimental data.
Sensitivity analysis
A systematic procedure for investigating the range of behaviours
in complex dynamic models is Latin Hypercube Sampling (LHS) –
see [25]. It is a statistical analysis technique that permits a
comprehensive exploration of the model parameter space in a
computationally efficient manner. Its efficiency stems from the fact
that each value of each parameter is used only once. The model is
run for different combinations of model parameters and the outputs
can be described by basic descriptive statistics, though here we are
primarily focussed on the robustness of the qualitative behaviours of
the model. Essentially the issue is one of investigating the effect of
uncertainty in determining model parameters on the model outputs.
It is not our intention to review the LHS methodology here, rather
we note that it has been successfully applied to deterministic
mathematical epidemiology models of comparable size and
complexity to the immunological model described above [26,27]
and in systems engineering applications as well [25].
The application of LHS to our immunological model was
straightforward and we assumed that the model parameters have
uniformly distributed probability distribution functions (pdfs)
spanning a range from a given minimum to a given maximum;
at this stage we have no other information that permits more
complex pdfs to be proposed so we used the simplest represen-
tation. Following the standard LHS procedure we generated an
appropriate LHS table, selected the resulting parameter combi-
nations and performed ten times the number of simulations
required to fully sample the parameter space [25]. The parameters
used in the model are itemised in Table 2.
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